Replies to post #14689 on Aethlon Medical Inc (AEMD)

[laker5]

16-Mar-2015

Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur


ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On March 12, 2015, Aethlon Medical, Inc. ("we") entered into a modification of our contract with the Defense Advanced Research Projects Agency, part of the Department of Defense. We entered into the initial contract on September 30, 2011. The Defense Advanced Research Projects Agency entered into the contract modification in an effort to accelerate our production of the Aethlon Hemopurifier? by modifying specific milestones we must achieve under the contract as follows:

? Milestone M6 under year 3 of the contract:

o Modified milestone: Define Aethlon's GMP manufacturing process [for the Aethlon Hemopurifier?] and revise and upgrade Aethlon's quality procedures and policies to the current state of the art.

o Previous milestone: Demonstrate the safety of at least one prototype device within an optimized fluidic circuit architecture preventing clotting in a 24-hour experiment in vivo at a blood flow rate of 200 ml/min using either pigs or dogs.

? Milestone 2.5.1.1 under year 4 of the contract:

o Modified milestone: Complete Aethlon's GMP procedure [for the Aethlon Hemopurifier?] and establish and maintain all GMP documentation for the company.

o Previous milestone: Develop additional optimized configuration(s) of hemopurification device(s) that contain(s) a combination of hemofilters, plasma filters, and affinity columns.

? Milestone M11 under year 4 of the contract:

o Modified milestone: Develop a strategic plan for developing an alternate method of producing GNA [Galanthus nivalis agglutinin, the affinity lectin immobilized within the Aethlon Hemopurifier?] by cloning the gene into an alternate vector and identify potential partners for such production.

o Previous milestone: Demonstrate the safety of an additional prototype device within an optimized fluidic circuit architecture preventing clotting in a 24-hour experiment in vivo at a blood flow rate of 200 ml/min using either pigs or dogs.

The contract is priced on a fixed-price basis. The contract modification did not change the fixed payments due to us upon our achievement of the milestones.